Acadia designs PhIII to reduce placebo effect in Parkinson's psychosis
This article was originally published in Scrip
Executive Summary
Acadia Pharmaceuticals has redesigned its Phase III clinical trial for pimavanserin in the treatment of Parkinson's disease psychosis (PDP) to avoid the study's failure due to a placebo effect noted outside of North America.